JPMorgan Funds - Thematics - Genetic Therapies Fund C (dist) GBP
Category Sector Equity Biotechnology
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price
£78.96
£-1.17 (-1.46%)
Fund Code
JMGTI
BMXMZ45
LU2314628723
Prices updated as at 13 Nov 2026
Prices in GBP
Investment objective
The fund seeks to achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.
Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide or Product Summary document
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Growth
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk & rating
- Management
| Fund status | Open |
| Fund type | SICAV |
| Fund manager | Yazann Romahi, Aijaz Hussain |
| 84.72 | |
| 65.16 | |
| Fund comparative index | MSCI ACWI NR USD |
| - | |
| - | |
| 0.56 | |
| 0.03 | |
| 0.00 | |
| Sector Equity Biotechnology | |
| No | |
| Fund provider | JPMorgan Asset Management (Europe) S.à r.l. |
| Share class launch date | 17 Mar 2021 |
| £290.39m | |
| - | |
| - | |
| - | |
| Annually |
Please note that some funds may have small additional incidental charges that are not shown here. Where these charges do exist they are included within the variable ongoing costs in the Pre-sale Illustration.